MENLO PARK, Calif. and MILAN, Italy, March 13, 2024 (GLOBE NEWSWIRE) -- Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, and Olon Group, the global leader in developing and manufacturing active pharmaceutical ingredients (APIs) for CDMO (contract development and manufacturing organization) and generic markets, today announced an ongoing partnership to leverage Olon’s vast fermentation infrastructure to manufacture Antheia’s early products..

加利福尼亚州门洛帕克和意大利米兰，2024年3月13日（环球通讯社）——改变基本药物供应链的药物成分制造商安西亚，以及为CDMO（合同开发和制造组织）和仿制药市场开发和制造活性药物成分（API）的全球领导者奥隆集团，今天宣布了一项正在进行的合作关系，以利用Olon庞大的发酵基础设施来制造安西亚的早期产品。。

Antheia and Olon established this partnership in 2022 to leverage Olon’s fermentation sites across Italy. Olon has since played a pivotal role as a CDMO for scaling Antheia’s biomanufacturing processes and producing its Biosynthetic KSMs (key starting materials) and APIs. Looking to 2024 and beyond, Antheia will continue to partner with Olon to unlock additional capacity to meet international demand for its first products, including thebaine..

Antheia和Olon于2022年建立了这一合作关系，以利用Olon在意大利各地的发酵场地。此后，Olon作为CDMO在扩大安西亚生物制造过程和生产其生物合成KSM（关键起始材料）和API方面发挥了关键作用。展望2024年及以后，安西亚将继续与奥隆合作，释放更多产能，以满足包括蒂巴恩在内的首批产品的国际需求。。

“The third-party partners we work with are a huge part of our success, so finding the right CDMO to help bring our first products to industrial scale efficiently and rapidly was a critical decision early in our commercialization journey,” said Zack McGahey, COO of Antheia. “Olon is a well-respected CDMO of high-quality pharmaceutical products and a trusted partner to us as we continue our work together to ship our first products later this year and ultimately, transform essential medicine supply chains.”.

Antheia首席运营官扎克·麦加希（Zack McGahey）表示：“与我们合作的第三方合作伙伴是我们成功的重要组成部分，因此找到合适的CDMO来帮助我们的第一批产品高效快速地实现工业规模是我们商业化进程早期的一个关键决定。”。“Olon是备受尊敬的高质量药品CDMO，也是我们值得信赖的合作伙伴，我们将继续合作，在今年晚些时候推出首批产品，并最终改变基本药物供应链。”。

Olon Biotech – a division of Olon Group - has more than 50 years of experience providing high-quality fermentation manufacturing services and is a globally licensed API manufacturer. With 5,000 cubic meters of fermentation capacity installed within its sites, Olon is one of the leading global CDMOs for biomanufacturing.

Olon Biotech是Olon Group的一个部门，拥有50多年提供高质量发酵生产服务的经验，是一家获得全球许可的API制造商。Olon拥有5000立方米的发酵能力，是全球领先的生物制造CDMOs之一。

Olon’s extensive global infrastructure and deep industry expertise were instrumental to Antheia’s recent commercial milestones for its first product, thebaine..

Olon广泛的全球基础设施和深厚的行业专业知识有助于Antheia最近为其首款产品thebaine取得商业里程碑。。

“This successful partnership has yielded significant results and represents a promising future for pharma supply chains. Over the last five years, we have massively invested in our Biotech Centers, generating a significant increase in capacity and upgrading production processes for greater efficiency, and importantly, reducing the environmental impact of our production,” said Maurizio Sartorato, VP of Olon Biotech..

“这种成功的合作关系取得了重大成果，为制药供应链带来了光明的未来。在过去五年中，我们对生物技术中心进行了大量投资，大幅提高了产能，升级了生产流程，提高了效率，重要的是，减少了生产对环境的影响。”Olon Biotech副总裁Maurizio Sartorato说道。。

Antheia and Olon will both be in attendance at DCAT Week in NYC from March 18-21. To meet with either team at the event, please see contact information below.

Antheia和Olon都将参加3月18日至21日在纽约举行的DCAT周。要在活动中与任一团队会面，请参阅下面的联系信息。

Antheia Media Contact:

Anthea媒体联系人：

Mission North for Antheia

安西亚北使团

antheia@missionnorth.com

antheia@missionnorth.com

Antheia DCAT Contact:

Anthea DCAT联系人：

info@antheia.bio

info@antheia.bio

Olon Media Contact:

Olon媒体联系人：

Sabrina Spina

Sabrina Spina

sspina@olonspa.it

sspina@olonspa.it